Stocktoria
Summit Therapeutics Inc. SMMT
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2004-10-14
Summit Therapeutics Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $705,000 | $1.8M | $860,000 | $743,000 |
| R&D expense | — | — | $59.5M | $52.0M | $85.4M | $53.3M | $39.8M |
| Operating income | — | -$226.0M | -$609.6M | -$72.1M | -$86.2M | -$53.2M | -$27.5M |
| Interest expense | — | — | — | $4.4M | $242,000 | $255,000 | $291,000 |
| Income tax | $0 | $0 | $0 | — | $0 | -$213,000 | $36,000 |
| Net income | -$1.1B | -$221.3M | -$614.9M | -$78.8M | -$88.6M | -$52.7M | -$29.1M |
| EPS (diluted) | $-1.44 | $-0.31 | $-0.99 | $-0.41 | $-0.67 | $-0.76 | $-0.89 |
| Operating cash flow | -$322.9M | -$142.1M | -$76.8M | -$41.6M | -$72.6M | -$48.1M | -$20.8M |
| Free cash flow | -$323.6M | -$142.2M | -$76.9M | -$42.2M | -$72.9M | -$48.5M | -$21.0M |
| Cash & equivalents | $225.3M | $104.9M | $71.4M | $348.6M | $71.8M | $66.4M | $63.8M |
| Total assets | $751.2M | $435.6M | $202.9M | $664.2M | $113.4M | $102.5M | $96.2M |
| Total liabilities | $92.3M | $46.8M | $125.3M | $537.5M | $30.1M | $23.0M | $17.4M |
| Shareholders' equity | $658.9M | $388.7M | $77.7M | $126.7M | $83.3M | $79.5M | $78.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | -100.0% | -61.0% | +110.3% | +15.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.